Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...
The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback